|
Jun 13
|
Chipotle, McDonald's initiated: Wall Street's top analyst calls
|
|
Jun 12
|
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
|
|
May 13
|
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 13
|
Cara Therapeutics Reports First Quarter 2024 Financial Results
|
|
May 6
|
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
|
|
Apr 2
|
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 7
|
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
|
|
Mar 7
|
7 F-Rated Stocks to Sell in March 2024
|
|
Mar 7
|
Analysts Have Made A Financial Statement On Cara Therapeutics, Inc.'s (NASDAQ:CARA) Yearly Report
|
|
Mar 6
|
Cara Therapeutics Full Year 2023 Earnings: Misses Expectations
|
|
Mar 5
|
Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2023 Earnings Call Transcript
|
|
Mar 5
|
Q4 2023 Cara Therapeutics Inc Earnings Call
|
|
Mar 4
|
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 4
|
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
|
|
Feb 21
|
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
|
|
Jan 22
|
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
|
|
Dec 19
|
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
|
|
Dec 18
|
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
|
|
Aug 10
|
Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript
|
|
Aug 8
|
Q2 2023 Cara Therapeutics Inc Earnings Call
|